Mail

New Zealand markets close in 5 hours 56 minutes

NZX 50
11,783.83
-52.21(-0.44%)
NZD/USD
0.5903
-0.0003(-0.05%)
ALL ORDS
7,898.90
+37.90(+0.48%)
OIL
82.60
-0.13(-0.16%)
GOLD
2,393.80
-4.20(-0.18%)

Bristol-Myers Squibb Company (BMY)

NYSE - NYSE Delayed price. Currency in USD

Add to watchlist

48.30

+0.46

(+0.96%)

At close: 04:00PM EDT

48.30

0.00

(0.00%)

After hours:

07:02PM EDT

Trade prices are not sourced from all markets

Previous close	47.84
Open	47.93
Bid	48.21 x 900
Ask	48.22 x 1000
Day's range	47.62 - 48.40
52-week range	47.58 - 70.94
Volume	10,908,239
Avg. volume	15,853,241

Market cap	97.892B
Beta (5Y monthly)	0.39
PE ratio (TTM)	12.51
EPS (TTM)	N/A
Earnings date	N/A
Forward dividend & yield	2.40 (5.02%)
Ex-dividend date	04 Apr 2024
1y target est	N/A

Press releases

Business Wire
KRAZATI (adagrasib) in Combination with Cetuximab Demonstrates Clinically Meaningful Activity as a Targeted Treatment Option for Patients with Previously Treated KRAS G12C-Mutated Locally Advanced or Metastatic Colorectal Cancer (CRC)
PRINCETON, N.J., April 08, 2024--KRAZATI (adagrasib) in Combination with Cetuximab Demonstrates Clinically Meaningful Activity as a Targeted Treatment Option for Patients with.....
Business Wire
Bristol Myers Squibb Presents New Pooled Interim Long-Term Safety and Metabolic Outcomes Data from the EMERGENT Program Evaluating KarXT in Schizophrenia at the 2024 Annual Congress of the Schizophrenia International Research Society
PRINCETON, N.J., April 06, 2024--Bristol Myers Squibb Presents New Pooled Interim Long-Term Safety and Metabolic Outcomes Data from the EMERGENT Program Evaluating KarXT....
Business Wire
Bristol Myers Squibb Presents New Interim Long-Term Efficacy Data from the EMERGENT-4 Trial Evaluating KarXT in Schizophrenia at the 2024 Annual Congress of the Schizophrenia International Research Society
PRINCETON, N.J., April 06, 2024--BMS Presents New Interim Long-Term Efficacy Data from the EMERGENT-4 Trial Evaluating KarXT in Schizophrenia...